Evidence map›Paper›PMID 38843261›Full record

ArticlePloS one2024

Enhancing drug therapy in ostomy patients: Best practice recommendations for medication management.

Vivien Berger, Matthias Reeh, Martin Scherer, Steffen Härterich, Sven Möller, Eva-Maria Anette Wansing, Annika van der Linde, Claudia Langebrake

Abstract read
In one paragraph

Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Crohn's disease exacerbated by ghost pills of upadacitinib.Clinical journal of gastroenterology · 2025
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Vivien BergerHospital Pharmacy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.ORCID 0000-0002-6424-6013
Matthias ReehDepartment of General, Abdominal, Thoracic and Vascular Surgery, Katholisches Marienkrankenhaus, Hamburg, Germany.
Martin SchererDepartment of General Practice and Primary Care, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Steffen HärterichHospital Pharmacy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Sven MöllerDepartment of Urology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.
Eva-Maria Anette WansingHospital Pharmacy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Annika van der LindeHospital Pharmacy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Claudia LangebrakeHospital Pharmacy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOstomy surgery is a common procedure that poses various challenges for patients and healthcare professionals. There are numerous guidelines addressing different ostomy-related problems (ORPs) and supporting an interdisciplinary approach for ostomy care, but evidence-based literature for optimizing drug therapy after ostomy surgery is lacking.

aimTo investigate and characterize typical ORPs in relation to drug therapy and provide best practice recommendations from a pharmaceutical point of view.

methodsPatients with an ileo- or colostomy were consecutively enrolled in a prospective, interventional monocentric cohort study during hospitalization, with particular attention to medication. A clinical pharmacist assessed DRPs by performing level 3 medication reviews and patient interviews. Pharmacists' interventions (PIs) were evaluated by two senior clinical pharmacists and documented in DokuPIK (Documentation of Pharmacists' Interventions in the Hospital). Following interdisciplinary discussions, physicians either accepted or rejected the proposed changes in drug therapy. Comparisons were made between ileostomy and colostomy patients regarding type and extent of PIs.

resultsOut of the 80 patients included in the cohort, 54 (67.5%) had an ileostomy and 26 (32.5%) a colostomy. In this study, 288 PIs were documented (234 ileostomy vs. 54 colostomy), of wich 94.0% were accepted and implemented by the physicians. The most common reason for PIs in both subgroups (29.6% ileostomy vs. 26.1% colostomy) was a missing drug although indicated (e.g. no loperamide, but high stoma output). The proportion of PIs associated with the ostomy was higher in ileostomy patients (48.3% ileostomy vs. 31.5% colostomy; p = 0.025). Typical ORPs were extracted and analyzed as case studies including recommendations for their respective management and prevention.

conclusionThis study highlights the importance of clinical pharmacists being a part of interdisciplinary teams to collaboratively improve ostomy care and patient safety. Especially ileostomy patients are more vulnerable for ORPs in the context of drug therapy and need to be monitored carefully.

Indexed as

PharmacistsAdultAgedAged, 80 and overColostomyFemaleHumansIleostomyMaleMedication Therapy ManagementMiddle AgedOstomyPractice Guidelines as TopicProspective Studies

Identifiers

PMID38843261
PMCPMC11156294

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.